Posted in | Oncology

Epithelial Mesenchymal Transition in Carcinoma Webinar

Review striking similarities between the operating mechanisms of EMT and carcinoma with leading expert, Professor Jean Paul Thierry.

Listen in as Professor Thierry, Research Director Emeritus at the Institut Gustave Roussy Comprehensive Cancer Center, discusses a number of studies supporting the concept that EMT contributes to tumor progression.

Meet the Presenter

Jean Paul Thiery is currently Research Director Emeritus at the Institut Gustave Roussy Comprehensive Cancer Center at Villejuif, and at the CNRS unit Matter and Complex Systems in Paris, France, as well as a Visiting Professor at the School of Medicine of National University of Singapore (NUS), and at CCBIO University of Bergen, Norway.

Jean Paul serves as a Scientific Advisor of the Dean of Medical School NUS, Singapore, and in a number of other Institutions worldwide. He was until June 2015, Professor and Head of the Biochemistry Department, School of Medicine at NUS. He has also served a joint appointment as Research Director at IMCB A*STAR Singapore, and Senior Principal Investigator at the Cancer Science Institute at NUS.

After his PhD studies at the University of Paris, Jean Paul completed his postdoctoral research with Gerald Edelman (Nobel Laureate) at the Rockefeller University, where his studies led to the discovery of N-CAM- the first intercellular adhesion molecule to be identified. In 2006, Jean Paul moved to Singapore from his position as Head of Translational Research at the Medical Division of the Comprehensive Cancer Center of Institut Curie in Paris, and before that, Head of the Cell Biology Department at the Institut Curie until 2003. His influential works include pioneering studies in cell adhesion and migration in early embryogenesis and in elucidating the roles of growth factors and adhesion signaling molecules in Epithelial-Mesenchymal Transitions (EMT).

Jean Paul is credited as the first to propose that EMT control invasion and dissemination while the reverse process, MET, is required for the development of clinically detectable metastases in carcinoma. His current research’s focus is to unravel the mechanisms of invasion and metastasis of carcinoma cells, while his seminal contributions to bladder carcinoma studies have led to the discovery of the molecular mechanisms underlying the formation of superficial or invasive tumors. Currently, his research is focusing on oncogenomics and the creation of functional approaches to characterize bladder, lung breast, and ovarian carcinoma progression- with the ultimate goal to apply EMT-based therapeutic approaches in the near future.

Jean Paul is an EMBO and Academia Europea member. He has been made Chevalier (Knight) in the order the Legion d’Honneur , the highest distinction in France, in 2009.

Webinar Topics

  • Definition of EMT; its role in development
  • Mechanistic insight of EMT process
  • Current issues in controlling tumor progression
  • Ovarian and bladder carcinoma as models for the study of EMT
  • Can we use the EMT concept to improve or develop new therapeutic approaches

Other Webinars from Abcam

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.